Antithymocyte globulin in the management of cutaneous T cell lymphoma.

Four patients with cutaneous T cell lymphoma were treated with iv administered horse antithymocyte globulin. Evidence of a beneficial response was obtained in three of the four patients. Limited sensitivity of neoplastic T cells to complement-mediated lysis in the presence of the antithymocyte globulin was identified, suggesting that other mechanisms may be responsible for the observed clinical responses.